IMC Chicago’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $40.8M | Buy |
673,300
+37,300
| +6% | +$2.17M | 0.01% | 574 |
|
|
2025
Q4 | $34.3M | Buy |
636,000
+52,200
| +9% | +$2.51M | 0.01% | 621 |
|
|
2025
Q3 | $26.3M | Buy |
583,800
+11,300
| +2% | +$528K | 0.01% | 673 |
|
|
2025
Q2 | $26.5M | Buy |
572,500
+127,500
| +29% | +$6.26M | 0.01% | 586 |
|
|
2025
Q1 | $27.1M | Sell |
445,000
-127,200
| -22% | -$7.41M | 0.02% | 475 |
|
|
2024
Q4 | $32.4M | Sell |
572,200
-292,000
| -34% | -$16.3M | 0.02% | 451 |
|
|
2024
Q3 | $44.7M | Buy |
864,200
+88,000
| +11% | +$4.13M | 0.02% | 330 |
|
|
2024
Q2 | $32.2M | Buy |
776,200
+463,000
| +148% | +$20.7M | 0.02% | 391 |
|
|
2024
Q1 | $17M | Sell |
313,200
-35,100
| -10% | -$1.79M | 0.01% | 511 |
|
|
2023
Q4 | $17.9M | Buy |
348,300
+136,700
| +65% | +$7.18M | 0.01% | 490 |
|
|
2023
Q3 | $12.3M | Buy |
211,600
+43,400
| +26% | +$2.66M | 0.01% | 502 |
|
|
2023
Q2 | $10.8M | Buy |
168,200
+16,500
| +11% | +$1.11M | 0.01% | 495 |
|
|
2023
Q1 | $10.5M | Sell |
151,700
-43,500
| -22% | -$3.07M | 0.01% | 477 |
|
|
2022
Q4 | $14M | Sell |
195,200
-37,200
| -16% | -$2.8M | 0.02% | 380 |
|
|
2022
Q3 | $16.5M | Sell |
232,400
-10,700
| -4% | -$776K | 0.02% | 332 |
|
|
2022
Q2 | $18.7M | Buy |
243,100
+4,600
| +2% | +$350K | 0.03% | 304 |
|
|
2022
Q1 | $17.4M | Buy |
238,500
+9,000
| +4% | +$604K | 0.02% | 359 |
|
|
2021
Q4 | $14.3M | Buy |
229,500
+108,300
| +89% | +$6.35M | 0.01% | 423 |
|
|
2021
Q3 | $7.17M | Buy |
121,200
+5,600
| +5% | +$369K | 0.01% | 561 |
|
|
2021
Q2 | $7.72M | Buy |
115,600
+17,700
| +18% | +$1.15M | 0.01% | 505 |
|
|
2021
Q1 | $6.18M | Sell |
97,900
-21,900
| -18% | -$1.36M | 0.01% | 518 |
|
|
2020
Q4 | $7.43M | Buy |
119,800
+41,500
| +53% | +$2.55M | 0.01% | 463 |
|
|
2020
Q3 | $4.72M | Sell |
78,300
-24,200
| -24% | -$1.46M | 0.01% | 425 |
|
|
2020
Q2 | $6.03M | Buy |
102,500
+3,500
| +4% | +$209K | 0.01% | 341 |
|
|
2020
Q1 | $5.52M | Sell |
99,000
-108,900
| -52% | -$6.66M | 0.01% | 307 |
|
|
2019
Q4 | $13.3M | Buy |
207,900
+44,300
| +27% | +$2.54M | 0.03% | 177 |
|
|
2019
Q3 | $8.3M | Sell |
163,600
-1,400
| -0.8% | -$65.8K | 0.03% | 202 |
|
|
2019
Q2 | $7.48M | Sell |
165,000
-41,600
| -20% | -$1.94M | 0.02% | 215 |
|
|
2019
Q1 | $9.86M | Buy |
206,600
+131,600
| +175% | +$6.56M | 0.04% | 148 |
|
|
2018
Q4 | $3.9M | Buy |
+75,000
| New | +$4.03M | 0.01% | 249 |
|
Other funds holding BMY
VCM
VPM
IMC Chicago's BMY Position: Q1 2026 in Review
IMC Chicago sold out of Bristol-Myers Squibb (BMY) in Q1 2026, closing a stake of 45,935 shares — an estimated $2.68M sold.
IMC Chicago first reported a position in BMY in Q2 2019 and held it in 7 quarters. The position peaked at $15.8M in Q4 2019. 2,517 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- IMC Chicago reported no remaining Bristol-Myers Squibb position as of Q1 2026 after selling out during the quarter.
- IMC Chicago sold 45,935 Bristol-Myers Squibb shares in Q1 2026, an estimated $2.68M.
- IMC Chicago first reported a position in Bristol-Myers Squibb in Q2 2019 and held it in 7 quarters.
- IMC Chicago's Bristol-Myers Squibb position peaked at $15.8M in Q4 2019.
- 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on IMC Chicago's 13F filing for Q1 2026, filed 5 May 2026.